NovaTarg is approved for a $250,000 loan from the NC Biotech Center
NT1195 is selected as a drug candidate for the treatment of Type 2 Diabetes in patients with impaired renal function. IND-enabling studies begin.
NovaTarg has received $3.2 million in SBIR grant funding to further its discovery of tissue selective AMPK activators. NovaTarg plans to progress drug candidates for polycystic Kidney Disease and Type 2 Diabetes during this coming year.
Ken Batchelor interviewed for an article about NovaTarg’s drug discovery activities in CEO:CFO Magazine.
Dr Victoria Bae-Jump, MD, PhD, (UNC) has received a Collaborative Funding Grant (CFG) from the North Carolina Biotech Center (NCBC) to support research on NovaTarg’s AMPK activators as potential treatments for ovarian cancer.
NovaTarg, Inc receives $50,000 as a matching grant from the NC Dept of Commerce for discovery of a new drug for hepatocellular carcinoma (HCC) – the most common type of liver cancer and the third leading cause of cancer deaths worldwide.
NovaTarg has filed 2 provisional patents to protect the intellectual property associated with our lead AMPK activators for metabolic disease, cancer and viral diseases.
NovaTarg has received Phase 1 SBIR funding for its liver cancer project – ‘Novel and Selective AMPK Activators for the Treatment of Hepatocellular Carcinoma’. This funding will allow us to fully demonstrate the potential for our approach to deliver efficacy for malignant indications.
NovaTarg has been awarded a Phase 2 SBIR grant to extend its studies on AMPK activators for type 2 diabetes (T2D). This grant will run for a 2 year period in a collaboration with Zen-Bio which is planned to culminate in the discovery of a new medicine to treat T2D.
NovaTarg receives 2 SBIR Phase 1 grants to progress tissue selective AMPK activators for the treatment of type 2 diabetes and polycystic kidney disease
NovaTarg outlines patent covering a tissue selective AMPK activator
NovaTarg Therapeutics featured in Startup magazine
Dr Nick Livingston and Dr Jeff Cobb join NovaTarg Therapeutics
NovaTarg receives a $30K loan from the NC Biotech Center
Successful Phase 1 SBIR application to support work on type 2 diabetes program
Three Qualified Therapeutic Discovery Program grants awarded to NovaTarg. Total value of this award is $712,000
NovaTarg Inc founded by Ken Batchelor with the intention of discovering innovative drugs for the treatment of metabolic diseases and cancer